SG11202111244XA - Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases - Google Patents
Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseasesInfo
- Publication number
- SG11202111244XA SG11202111244XA SG11202111244XA SG11202111244XA SG11202111244XA SG 11202111244X A SG11202111244X A SG 11202111244XA SG 11202111244X A SG11202111244X A SG 11202111244XA SG 11202111244X A SG11202111244X A SG 11202111244XA SG 11202111244X A SG11202111244X A SG 11202111244XA
- Authority
- SG
- Singapore
- Prior art keywords
- pdgfra
- mediated diseases
- pyrrolotriazine derivatives
- treating kit
- kit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833529P | 2019-04-12 | 2019-04-12 | |
| US201962911016P | 2019-10-04 | 2019-10-04 | |
| US201962930240P | 2019-11-04 | 2019-11-04 | |
| PCT/US2020/027177 WO2020210293A1 (en) | 2019-04-12 | 2020-04-08 | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111244XA true SG11202111244XA (en) | 2021-11-29 |
Family
ID=70416596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111244XA SG11202111244XA (en) | 2019-04-12 | 2020-04-08 | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20220153748A1 (en) |
| EP (1) | EP3953357B1 (en) |
| JP (1) | JP2022526850A (en) |
| KR (1) | KR20220025704A (en) |
| CN (1) | CN113939515B (en) |
| AU (1) | AU2020272743A1 (en) |
| BR (1) | BR112021020441A2 (en) |
| CA (1) | CA3136802A1 (en) |
| CL (1) | CL2021002656A1 (en) |
| CO (1) | CO2021015113A2 (en) |
| DK (1) | DK3953357T3 (en) |
| EC (1) | ECSP21080096A (en) |
| IL (1) | IL287168A (en) |
| MA (1) | MA55604A (en) |
| MX (1) | MX2021012469A (en) |
| PE (1) | PE20212331A1 (en) |
| SG (1) | SG11202111244XA (en) |
| TW (1) | TW202104231A (en) |
| WO (1) | WO2020210293A1 (en) |
| ZA (1) | ZA202108104B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021517902A (en) * | 2018-04-16 | 2021-07-29 | 深▲チェン▼市塔吉瑞生物医薬有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ， Ｉｎｃ． | Substituted pyrorotriazine compounds and their pharmaceutical compositions and their use |
| US20240010652A1 (en) * | 2020-10-14 | 2024-01-11 | Blueprint Medicines Corporation | Compositions and methods for treating kit- and pdgfra-mediated diseases |
| WO2022081626A1 (en) * | 2020-10-14 | 2022-04-21 | Blueprint Medicines Corporation | Compositions and methods for treating kit-and pdgfra-mediated diseases |
| CN118119621A (en) | 2021-03-03 | 2024-05-31 | 缆图药品公司 | Synthetic methods and intermediates for preparing compounds useful for treating KIT and PDGFRA mediated diseases |
| JP2024509276A (en) | 2021-03-10 | 2024-02-29 | ブループリント メディシンズ コーポレイション | Salts and solid forms of kinase inhibitors |
| CN113278023B (en) * | 2021-07-22 | 2021-10-15 | 上海睿跃生物科技有限公司 | Nitrogen-containing heterocyclic compound and preparation method and application thereof |
| WO2023081923A1 (en) * | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61238784A (en) | 1985-04-17 | 1986-10-24 | Sumitomo Seiyaku Kk | Succinimide derivative and its acid adduct |
| TR200103352T2 (en) | 1999-05-21 | 2005-03-21 | Bristol-Myers Squibb Company | Kinase pyrolotriazine inhibitors |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| WO2001025220A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
| SE0102616D0 (en) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| AU2003231034B2 (en) | 2002-04-23 | 2009-03-05 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| US7468376B2 (en) | 2003-02-27 | 2008-12-23 | Palau Pharma, S.A. | Pyrazolopyridine derivates |
| AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2006028524A2 (en) | 2004-04-29 | 2006-03-16 | Pharmix Corporation | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CA2627839C (en) | 2005-11-02 | 2014-08-19 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CA2636701C (en) | 2006-01-27 | 2014-08-05 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors |
| PL2041138T3 (en) | 2006-07-07 | 2014-11-28 | Bristol Myers Squibb Co | Pyrrolotriazine kinase inhibitors |
| CN101808693A (en) | 2007-07-25 | 2010-08-18 | 百时美施贵宝公司 | Triazine kinase inhibitors |
| ES2413806T3 (en) | 2008-03-20 | 2013-07-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| WO2010144345A1 (en) | 2009-06-08 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
| EP2532659A1 (en) | 2009-07-07 | 2012-12-12 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| JP2013519732A (en) | 2010-02-17 | 2013-05-30 | アムジエン・インコーポレーテツド | Arylcarboxamide derivatives as sodium channel inhibitors for the treatment of pain |
| WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| CN102040494A (en) | 2010-11-12 | 2011-05-04 | 西北师范大学 | Method for preparing p-fluorobenzaldehyde |
| CN104981247A (en) | 2012-09-06 | 2015-10-14 | 普莱希科公司 | Compounds and methods for kinase modulation, and indications therefor |
| SI2935248T1 (en) | 2012-12-21 | 2018-05-31 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| PL3057969T3 (en) | 2013-10-17 | 2018-11-30 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| JP2018521076A (en) | 2015-07-24 | 2018-08-02 | ブループリント メディシンズ コーポレイション | Compounds useful for treating diseases associated with KIT and PDGFR |
| WO2018183712A1 (en) * | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| CN109400610A (en) | 2017-08-18 | 2019-03-01 | 浙江海正药业股份有限公司 | Pyrrolo-triazine analog derivative, preparation method and its purposes in medicine |
| CN108191874B (en) | 2018-01-16 | 2019-11-29 | 成都施贝康生物医药科技有限公司 | A kind of C-Kit inhibitor and its application |
| TW202039862A (en) | 2018-11-12 | 2020-11-01 | 美商藍印藥品公司 | Avapritinib resistance of kit mutants |
| CN110950872A (en) | 2019-12-25 | 2020-04-03 | 武汉九州钰民医药科技有限公司 | Method for preparing targeted anticancer drug avapritinib |
| CN110938077B (en) | 2019-12-25 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | Method for synthesizing Avapritinib |
-
2020
- 2020-04-08 PE PE2021001699A patent/PE20212331A1/en unknown
- 2020-04-08 SG SG11202111244XA patent/SG11202111244XA/en unknown
- 2020-04-08 EP EP20721083.2A patent/EP3953357B1/en active Active
- 2020-04-08 US US17/602,770 patent/US20220153748A1/en active Pending
- 2020-04-08 TW TW109111858A patent/TW202104231A/en unknown
- 2020-04-08 CN CN202080042732.0A patent/CN113939515B/en active Active
- 2020-04-08 DK DK20721083.2T patent/DK3953357T3/en active
- 2020-04-08 MA MA055604A patent/MA55604A/en unknown
- 2020-04-08 KR KR1020217036868A patent/KR20220025704A/en unknown
- 2020-04-08 AU AU2020272743A patent/AU2020272743A1/en active Pending
- 2020-04-08 WO PCT/US2020/027177 patent/WO2020210293A1/en unknown
- 2020-04-08 JP JP2021560255A patent/JP2022526850A/en active Pending
- 2020-04-08 BR BR112021020441A patent/BR112021020441A2/en unknown
- 2020-04-08 CA CA3136802A patent/CA3136802A1/en active Pending
- 2020-04-08 US US16/842,969 patent/US10829493B2/en active Active
- 2020-04-08 MX MX2021012469A patent/MX2021012469A/en unknown
-
2021
- 2021-10-11 IL IL287168A patent/IL287168A/en unknown
- 2021-10-12 CL CL2021002656A patent/CL2021002656A1/en unknown
- 2021-10-21 ZA ZA2021/08104A patent/ZA202108104B/en unknown
- 2021-11-09 CO CONC2021/0015113A patent/CO2021015113A2/en unknown
- 2021-11-12 EC ECSENADI202180096A patent/ECSP21080096A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220153748A1 (en) | 2022-05-19 |
| EP3953357B1 (en) | 2024-04-17 |
| CA3136802A1 (en) | 2020-10-15 |
| DK3953357T3 (en) | 2024-06-10 |
| KR20220025704A (en) | 2022-03-03 |
| BR112021020441A2 (en) | 2021-12-14 |
| ZA202108104B (en) | 2024-02-28 |
| CO2021015113A2 (en) | 2022-02-28 |
| EP3953357A1 (en) | 2022-02-16 |
| MA55604A (en) | 2022-02-16 |
| WO2020210293A1 (en) | 2020-10-15 |
| US10829493B2 (en) | 2020-11-10 |
| JP2022526850A (en) | 2022-05-26 |
| US20200325141A1 (en) | 2020-10-15 |
| ECSP21080096A (en) | 2022-02-25 |
| CL2021002656A1 (en) | 2022-08-26 |
| MX2021012469A (en) | 2022-01-18 |
| PE20212331A1 (en) | 2021-12-14 |
| IL287168A (en) | 2021-12-01 |
| CN113939515B (en) | 2024-06-18 |
| AU2020272743A1 (en) | 2021-11-11 |
| TW202104231A (en) | 2021-02-01 |
| CN113939515A (en) | 2022-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3953357T3 (en) | Pyrrolotriazine derivatives for treating KIT- and PDGFRA-mediated diseases | |
| IL277190A (en) | Methods for treating hpv-associated diseases | |
| PL3600309T3 (en) | Therapeutic combinations for treating liver diseases | |
| RS63787B1 (en) | Macrocyclic compounds for treating diseases | |
| IL288523A (en) | Compounds for treatment of pd-l1 diseases | |
| IL277333A (en) | Methods for treating ocular diseases | |
| IL287907A (en) | Methods for treating cancer | |
| IL291735A (en) | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases | |
| EP3796891A4 (en) | Therapeutic constructs for treating cancer | |
| SG11202108636SA (en) | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | |
| EP4034128A4 (en) | Method for inducing tumor regression | |
| SG11202008718UA (en) | Combination therapy for cardiovascular diseases | |
| IL291565A (en) | Methods for treating hyperphenylalaninemia | |
| IL290770A (en) | Compounds and methods for treating oxalate-related diseases | |
| IL282703A (en) | Novel compounds useful for treating cardiovascular diseases | |
| IL276639A (en) | Agents and methods for treating dysproliferative diseases | |
| GB201909468D0 (en) | Compounds for treating cancer | |
| IL289436A (en) | Methods for treating ocular diseases | |
| IL286680A (en) | Medicament for treating cancer | |
| SG11202110659SA (en) | Method for treating ocular diseases | |
| EP3941921A4 (en) | Therapeutic methods for treating hepatitis b | |
| EP3810126A4 (en) | Disease modifying methods for treating neurodegenerative diseases using nootropic agents | |
| GB201908885D0 (en) | Therapeutic compounds | |
| EP3781130A4 (en) | Therapeutic constructs for treating cancer | |
| EP4058063A4 (en) | Methods for treating diseases |